Comparison

Anti-RelB Antibody [17.3] European Partner

Item no. ANTI-A278721-50
Manufacturer Antibodies.com
Amount 50 ug
Category
Type Antibody Primary
Format Liquid
Applications WB, IF, IP, ICC, IHC-P
Clone 17.3
Specific against Human (Homo sapiens), Mouse (Murine, Mus musculus), Monkey (Cynomolgus, Simian), Rhesus macaque
Host Mouse
Isotype IgG1
Conjugate/Tag Unconjugated
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Available
Storage Conditions
Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.
Product Description
Mouse monoclonal [17.3] antibody to Rel B.
Clonality
Monoclonal
Immunogen
Recombinant protein derived from C-terminus of human RelB protein.
Concentration
500 µg/ml
Manufacturer - Formulation
Supplied in Phosphate Buffered Saline with 0.1% Sodium Azide.
Purification
Protein A affinity chromatography of tissue culture supernatant.
Recommended dilutions
ICC: 1 µg/ml, IF: 1 µg/ml, IHC-P: 1:10 - 1:50, WB: 1 - 2 µg/ml
Molecular weight
Approximately 63 kDa in THP-1 cell lysate, Daudi cell lysate, and Raji cell lysate
Manufacturer - Specificity
This antibody recognises the transcription factor RelB, also known as I-Rel. RelB is encoded by the v-rel avian reticuloendotheliosis viral oncogene homolog B gene and is a critical component of the NF-kappa-B pathway.Upon cleavage of the NF-kappa-B p105 and p100 subunits into the NF-kappa-B p50 and p52 subunits, RelB forms RelB-p50 and RelB-p52 heterodimers. These dimers act as activators of transcription by binding to kappaB sites present on DNA. RelB-p50 and RelB-p52 binding induces the expression of genes mediating immune responses, inflammation and apoptosis. Misregulation of the NF-kappa-B pathway has been implicated in a variety of disease states including autoimmunity and cancer. As the NF-kappa-B pathway has been demonstrated to be constitutively active in a large group of tumors, developing NF-kappa-B inhibitors has emerged as a new cancer therapy approach (Chaturverdi et al. 2011 and Baud and Karin et al. 2009).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close